WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2021> 27> 1

Volume: 27 Issue: 1

1. Old hepatitis B virus never dies: It just hides itself within the host genome Page:107—109
2. Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma Page:103—106
3. Recent updates on the management of autoimmune hepatitis Page:58—69
4. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease Page:22—43
5. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study Page:144—156
6. A dilemma that probably would never resolve Page:219—220
7. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance Page:207—218
8. The cut-off value of transient elastography to the value of hepatic venous pressure gradient in alcoholic cirrhosis Page:197—206
9. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis Page:186—196
10. Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients Page:175—185
11. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan Page:136—143
12. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis Page:110—124
13. Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care Page:100—102
14. Elimination of hepatitis C: What would be the practical approach? Page:97—99
15. Alcohol-related cirrhosis: The most challenging etiology of cirrhosis is more burdensome than ever Page:94—96
16. The cutoff of transient elastography for the evaluation of portal hypertension should be different according to the etiology? Page:91—93
17. Metabolic disease as a risk of hepatocellular carcinoma Page:87—90
18. Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try Page:83—86
19. Drug-drug interactions with direct-acting antivirals — less is more Page:81—82
20. The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future Page:70—80
21. Current understanding of primary biliary cholangitis Page:1—21
22. Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study Page:125—135
23. Obesity and the risk of primary liver cancer: A systematic review and meta-analysis Page:157—174
24. Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective Page:44—57

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.